Appendix C
Workshop Agenda
WORKSHOP PART 1
THURSDAY, JULY 22, 2021
11:00 AM–1:00 PM ET
11:00 AM | Welcome Remarks, Workshop Overview, and Goals |
Kenneth Castro, workshop co-chair | |
Gail Cassell, workshop co-chair | |
11:05 AM | Opening Addresses: Current Status and Urgency of Ending TB Around the Globe |
Jim Yong Kim (Global Infrastructure Partners) | |
Salmaan Keshavjee (Harvard Medical School) | |
Eric Rubin (New England Journal of Medicine) |
Moderator: Lucica Ditiu | |
11:30 AM | Diagnostics |
Soumya Swaminathan (World Health Organization) | |
11:40 AM | Vaccines and Therapeutics |
Emilio Emini (Bill & Melinda Gates Foundation) |
11:50 AM | Critical Need for New Business Models |
Kevin Outterson (Boston University School of Law) | |
12:00 PM | Discussion (50 min) |
12:55 PM | Wrap-up and Adjourn |
Gail Cassell, workshop co-chair | |
Kenneth Castro, workshop co-chair |
WORKSHOP—PART TWO
TUESDAY, SEPTEMBER 14, 2021
11:00 AM–2:30 PM ET
11:00 AM | Welcome and Workshop Goals |
Peter Daszak, Chair, Forum on Microbial Threats, National Academy of Medicine; President, EcoHealth Alliance | |
Lucica Ditiu, moderator, Stop TB Partnership | |
11:05 AM | Sponsor Remarks |
Jennifer Adams, Senior Deputy Assistant Administrator, Bureau for Global Health, United States Agency for International Development | |
11:20 AM | Building a Tuberculosis-Free World: Progress Update |
Eric Goosby (University of California, San Francisco) | |
15 min Q&A | |
Realities of Multidrug-Resistant TB and Challenges for TB Control | |
Matteo Zignol (World Health Organization) | |
15 min Q&A |
12:15 PM | Rapid Acceleration of Diagnostics: The COVID-19 Experience |
Matthew McMahon (Director, Small Business Education and Entrepreneurial Development, NIH) | |
15 min Q&A | |
12:45 PM | Panel Discussion on Diagnostic Advances |
Point-of-Care Molecular Platform for Diagnosis of TB and Other Infectious Respiratory Diseases | |
Morten Ruhwald (FIND, the global alliance for diagnostics) | |
Platform Technologies for Detection of Multiple Agents | |
Zvi Marom (BATM) and Eran Zahavy (BATM) | |
Improving X-Ray Accessibility | |
Luan Vo (Friends for International Tuberculosis Relief) | |
Implementation Challenges with New TB Diagnostics | |
Kaiser Shen (USAID) | |
1:15 PM | Enhancing Adherence, Infection Control Capacities, and Cost-Effectiveness |
Expansion and Improvements to Contact Tracing and Engagement: Mobile or Digital Platforms from the COVID-19 Pandemic | |
Aamir Khan (IRD) | |
Telehealth and Digital Adherence Technologies | |
Bruce Thomas (The Arcady Group) | |
Innovative Strategies to Share the Costs of Investments in Health Care Systems by Partnering with Other Disease Burdens in LMICs | |
Monique K. Mansoura (MITRE) |
Infection Prevention | |
Edward Nardell (Harvard Medical School, Brigham and Women’s Hospital) | |
Management of Latent TB Infection: Gaps and Opportunities | |
Gavin Churchyard (The Aurum Institute) | |
2:15 PM | Reflections on Session 1 |
Lucica Ditiu | |
2:30 PM | Adjourn |
WORKSHOP PART 2
WEDNESDAY, SEPTEMBER 15, 2021
11:00 AM–2:30 PM ET
11:00 AM | Welcome and Session Goals |
Kent Kester, moderator, Sanofi Pasteur | |
11:05 AM | Using Existing Tools and New Technologies |
BCG Revaccination | |
Alex Schmidt (Bill & Melinda Gates Medical Research Institute) | |
Promising New Adjuvants and Late-Stage Clinical Development Vaccine Candidates | |
Steve Reed (University of Washington; HDT Bio) | |
How Host-Directed Therapies Can Change the Development Landscape | |
Daniel Kalman (Emory University) | |
Immune Mechanisms of Protection Against TB | |
Rhea Coler (Seattle Children’s Hospital) | |
12:00 PM | Transforming Treatment Options |
Charles Wells, moderator, Bill & Melinda Gates Medical Research Institute |
The Key to Success for Developing a New Regimen to Advance TB Treatment: Lessons from TBTC Study 31 (S31/A5349) | |
Payam Nahid (University of California, San Francisco) | |
What It Takes to Roll Out a New Treatment Regimen: Lessons from Drug-Resistant TB | |
Adrian Thomas (Johnson & Johnson) | |
Norbert Ndjeka (National Department of Health, Republic of South Africa) | |
Bringing Innovation to the Development of New Transformative TB Regimens | |
David Hermann (Bill & Melinda Gates Foundation) | |
Importance of Context-Specific Economic Analyses to Inform Future Program Design and Investment | |
Anna Vassall (London School of Hygiene & Tropical Medicine) | |
1:00 PM | Expert Reflections and Discussion on Critical Elements for Implementation |
Ezra Shimeles Tessera (TB Data, Impact Assessment and Communications Hub, USAID; John Snow, Inc.) | |
Richard Chaisson (Johns Hopkins University School of Medicine and Bloomberg School of Public Health) | |
2:15 PM | Reflections on Session 2 |
Kent Kester | |
Charles Wells | |
2:30 PM | Adjourn |
WORKSHOP PART 2
THURSDAY, SEPTEMBER 16, 2021
11:00 AM–2:30 PM ET
11:00 AM | Welcome: Session Goals and Bold Moves |
Peter Sands, moderator, The Global Fund |
11:10 AM | Opening Remarks |
Victor Dzau, President, National Academy of Medicine | |
11:15 AM | A Place for TB in the Pandemic Preparedness Agenda |
Tharman Shanmugaratnam, Senior Minister, Singapore, and co-chair, G20 High-Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response | |
11:50 AM | Achieving Synergy in Global Health Security Preparedness Against Respiratory Pathogens: Recognition of TB as a Leading Killer |
Peter Sands, moderator | |
John Bell (University of Oxford) | |
Bruce Gellin (The Rockefeller Foundation) | |
Rebecca Katz (Georgetown University, Center for Global Health Science and Security) | |
Michael Callahan (Massachusetts General Hospital; United Therapeutics) | |
1:05 PM | Making the Case for Financing TB Elimination |
Margaret Hamburg, moderator, Nuclear Threats Initiative | |
The Cost of Failing to Achieve the End TB Targets: A Full Economic Analysis | |
Michael Reid (University of California, San Francisco) | |
Why TB Is One of the Best Investments on the SDG Agenda | |
Bjorn Lomborg (Copenhagen Consensus Center) | |
Smart Investments in Ending TB | |
Mark Dybul (Georgetown University; Enochian BioSciences) | |
Implications for TB from the High-Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response | |
Amanda Glassman (Center for Global Development) |
2:00 PM | Closing Remarks |
Margaret Hamburg | |
Gail Cassell, workshop co-chair | |
Kenneth Castro, workshop co-chair | |
2:30 PM | Adjourn |
This page intentionally left blank.